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Biological effects of low-level exposures (BELLE) may be very important in characterizing the
potential health risks of environmental pollutants. Before some features of BELLE, such as effects
that may be modulated by adaptive or defense mechanisms, can be taken into greater
consideration in U.S. Environmental Protection Agency risk assessments, however, adequate
information on a toxicant's mode of action and answers to other questions are needed. - Environ
Health Perspect 106(Suppl 1):379-381 (1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-1/
379-381davis/abstract.html
Key words: risk assessment, mode of action, adaptation, defense mechanisms, beneficial
effects, U-shaped dose-response relationships
The effects of low-level exposures to
environmental pollutants are a matter
of particular importance to the U.S.
Environmental Protection Agency (U.S.
EPA). Extrapolation from experimental
high-dose effects to often much lower
environmentally relevant concentrations
introduces uncertainties in risk assess-
ment. Although the use of conservative
default assumptions about the nature of
dose-response relationships may be useful
for screening purposes and is generally
protective ofpublic health, ifevidence is
available to show that effects at high doses
clearly do not occur in the same manner at
low doses, then assumptions to the contrary
may ultimately prove counterproductive to
public health protection, particularly ifthey
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result in the expenditure of resources that
could more usefully be applied to reduce
other pollutants. For these and other reasons,
a fuller characterization and understanding
ofthe biological effects oflow-level expo-
sures (BELLE) will enable the U.S. EPA to
better serve its mission.
When assessing health risks U.S. EPA
scientists consider information on the mech-
anisms oftoxicity when such information is
available, as illustrated by the role ofalpha-
2u-microglobulin in producing male rat
kidney tumors and by the existence of
nongenotoxic carcinogens. However, as the
U.S. EPA's 1996 proposed cancerguidelines
(1) indicate, it is important to think more
broadly than the mechanism; that is, one
must consider the mode ofaction, which
encompasses all relevant mechanisms as well
as other factors that contribute to an agent's
influence on the development oftumors or
other toxic effects.
Among the questions to be addressed as
mode ofaction is considered are:
* Has a body ofdata been developed on
the agent that fits with a generally
accepted mode ofaction?
* Has a hypothesis on the mode of
action been published and has it
gained general scientific acceptance
through peer-reviewed research, or is it
still speculative?
* Is the proposed mode of action consis-
tent with generally agreed-on principles
and understanding ofcarcinogenesis?
* Is the mode of action reasonably
anticipated or assumed, in the absence
ofspecific data, to operate in humans?
How is this question influenced by
information on comparative uptake,
metabolism, and excretion patterns
across animals and humans?
* On average do humans appear more or
less sensitive to the mode ofaction than
animals? Have susceptible subpopula-
tions or individuals been identified or
are they likely to exist?
* Does the agent affect DNA either
directly or indirectly?
* Are there important determinants in car-
cinogenicity other than effects on DNA,
such as changes in cell proliferation
apoptosis, gene expression, immune
surveillance, or other influences?
Chronic animal studies may provide
important clues to potential modes of
action and the relevance ofanimal tumor
findings to humans. In this regard, impor-
tant factors to consider include tumor
types, e.g., those responsive to endocrine
influence or those produced by reactive
carcinogens; number of tumor sites,
sexes, studies, and species showing effects
or no effects; influence of route of expo-
sure; the spectrum of tumors (local or
systemic sites); and target organ or system
toxicity, e.g., urinary chemical changes
associated with stone formation or effects
on immune surveillance. Other important
factors include presence of proliferative
lesions, e.g., hepatic foci and/or hyper-
plasias; progression oflesions from preneo-
plastic to benign to malignant with dose
and time; ratio of malignant to benign
tumors as a function of dose and time;
time of appearance of tumors after expo-
sure begins; tumors invading locally,
metastasizing, and producing death;
tumors in laboratory animal sites with
high or low spontaneous historical inci-
dence; biomarkers in tumor cells, both
induced and spontaneous, e.g., DNA or
protein adducts, mutation spectra, chro-
mosome changes, or oncogene activation;
and shape of the dose-response curve in
the range oftumor observation, e.g., linear
versus profound change in slope.
Multisite and multispecies tumor effects
are often associated with mutagenic agents
or agents (e.g., dioxin) that affect the most
basic biological processes, whereas tumors
restricted to one sex or species may suggest
an influence limited by gender, strain, or
species. Late onset of tumors that are pri-
marily benign, that are at sites with a high
historical background incidence, or that
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show reversal of lesions on cessation of
exposure may point to a growth-promoting
mode ofaction.
The possibility that an agent may act
differently in different tissues or have more
than one mode ofaction in a single tissue
must also be kept in mind. This applies
equally to carcinogens and noncarcino-
gens. For example, even essential elements
have rather different effects (hence, differ-
ent modes of action) at different dose
ranges (2). For example, Se deficiency
results in a lowering ofglutathione peroxi-
dase but has no effect on succinic dehydro-
genase, whereas Se excess affects succinic
dehydrogenase as well as other sulfur-con-
taining amino acids. Also, Mn deficiency
may result in seizures but excess Mn pro-
duces a quite different pattern of neuro-
toxic effects. Consider too that Mn is
possibly protective against lung cancer in
smokers but excessive levels ofinhaled Mn
also raise potential neurotoxicity risks.
Mode of action is also relevant to the
selection ofa dose-response extrapolation
procedure. For example, a default assump-
tion of linearity is appropriate when the
mode of action involves gene mutation
because of DNA reactivity. If carcino-
genicity is secondary to toxic effects that
have a threshold, however, an assumption
ofnonlinearity may be more appropriate.
Both linear and nonlinear processes may
be involved if, for example, an agent is
both DNA reactive and is highly active as
a promoter at high doses.
The role of adaptive or defensive
mechanisms may also be considered in
risk assessment. Again, however, sufficient
information is needed to instill confidence
that the mode or modes ofaction are ade-
quately understood. Dioxin and poly-
cyclic aromatic hydrocarbons illustrate the
possibility of inducible enzyme pathways
that can yield either toxic metabolites or
detoxification. Thus, isolating adaptive
aspects alone or assuming that such mech-
anisms are always operative (i.e., in all indi-
viduals or at all dose/concentration levels)
may not be warranted. Nevertheless, it is
important to consider the extent to which
such adaptive ordefensive effects mayoccur.
When the effects induced byan agent are
notjust adaptive but even apparently benefi-
cial, as may be described by a U-shaped
dose-response relationship, assessing the
health risks posed by such an agent becomes
somewhat more complicated (3,4). Such
complications have arisen in deriving oral
reference doses for nutritionally essential
trace substances such as Se and Zn (5,6).
The U.S. EPA has no formal policy or
guidance on how to address these situa-
tions generally. Each case must be evalu-
ated individually, with care taken to avoid
deriving reference values that might overlap
with deficient levels of intake. After all,
nutritionally essential environmental pol-
lutants are the exception rather than the
rule. However, in evaluating agents show-
ing U-shaped dose-response relationships,
some questions should be considered:
* Beneficial compared to what? There may
be a tendency to presume that different
types ofeffects are arrayed across a dose
continuum such that a toxic effect
occurs at a high dose and a beneficial
effect occurs at a low dose. In fact, mul-
tiple effects may occur at any given dose
level and some such effects may be
judged beneficial whereas others may be
judged adverse. For example, caloric
restriction may enhance longevity in lab-
oratory animals but it may also affect
their reproductive function (7).
Similarly, moderate ethanol consump-
tion may be associated with lower risk of
cardiovascular morbidity but it may also
be associated with increased risk ofother
diseases (e.g., breast cancer) and injury
due to accidents (3). Although it is
worthwhile to bring attention to the
possibility ofbeneficial effects at low lev-
els ofexposure, the converse is clearly
even more important: risk assessors must
be careful to avoid focusing only on
apparent benefits and ignoring concur-
rent adverse effects. A certain relativity
of values may also come into play.
Consider the human dilemma ofquan-
tity versus quality oflife in the example
ofcaloric restriction. For some persons a
substantial reduction ofcaloric intake
for a potentially longer lifespan may
not be an acceptable trade off for the
perceived diminished quality oflife.
* Beneficial to whom? Even if it is
accepted that a beneficial effect is asso-
ciated with a certain level ofexposure
to a substance or agent on average, the
U.S. EPA is typically required to for-
mulate public health policy and set
standards in a manner to protect not
just the average person but susceptible
subpopulations as well (e.g., the young,
the elderly, those who suffer from dis-
eases such as asthma). The question
that arises is whether enough informa-
tion exists on the apparently beneficial
effects of an otherwise toxic agent to
justify confidence that these effects
would be generally experienced across
an entire population. There might be
some percentage ofthe population who,
possibly because of polymorphisms or
other factors, would experience only the
adverse aspects ofan agent and not the
beneficial effects that the average person
would receive.
Beneficial at what exposure level?
Although controlled experimental expo-
sures may be suggestive ofa U-shaped
dose-response relationship with appar-
ently beneficial effects at low levels, can
we necessarily relate low in the experi-
mental context to exposures in the actual
environment? To illustrate, some experi-
mental evidence from animals on con-
trolled diets suggests that ultra-trace
levels oflead may be nutritionally essen-
tial (8). Regardless ofwhether the animal
evidence is adequate to support this con-
clusion, perhaps the ultimate question is
whether such findings have any practical
relevance to anyone on earth, given the
global pervasiveness oflead and wide-
spread exposure to it. Dose-response
information is not enough to judge
risk. An adequate exposure assessment
is also needed and it may be that an
exposure assessment would show that
humans are already in the toxic range
ofthe dose continuum.
As U.S. EPA scientists, our position on
BELLE must be guided by scientific data.
Cogent data and arguments need to be
compiled and presented to support greater
awareness ofBELLE in the U.S. EPA's risk
assessment methods. At present it is not
clear that general principles pertaining to
BELLE exist for U.S. EPA scientists to
consider. Thus, those who wish to advance
the consideration of BELLE in public
health regulatory contexts bear a certain
burden ofproof to show enough evidence
to support a conclusion that a benefit actu-
ally results from low-level exposure to an
environmental pollutant.
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